We are live on
!
Find out more
BGI
B Group Inc Portfolio holdings
AUM
$135M
1-Year Est. Return
80%
This Fund
S&P 500
This Quarter
Est. Return
+12.24%
1 Year Est. Return
+80%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$130M
AUM Growth
+$13.2M
(+11%)
Cap. Flow
+$7.04M
Cap. Flow
% of AUM
5.42%
Top 10 Holdings %
Top 10 Hldgs %
89.61%
Holding
20
New
1
Increased
9
Reduced
3
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ultragenyx Pharmaceutical
RARE
|
+$2.25M |
| 2 |
Taysha Gene Therapies
TSHA
|
+$1.18M |
| 3 |
Praxis Precision Medicines
PRAX
|
+$609K |
| 4 |
Aura Biosciences
AURA
|
+$585K |
| 5 |
Sight Sciences
SGHT
|
+$322K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$8.22M |
| 2 |
BioNTech
BNTX
|
+$1.37M |
| 3 |
ETNB
89bio
ETNB
|
+$695K |
| 4 |
AKRO
Akero Therapeutics
AKRO
|
+$457K |
| 5 |
Assembly Biosciences
ASMB
|
+$140K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
ADMA Biologics
ADMA
$2.02B
| $42.2M | 32.48% |
2,317,542
| – | – |
|
|
2
Insmed
INSM
$23.5B
| $15.6M | 12.01% |
155,000
-107,500
| -41% | -$8.22M |
|
3
Zai Lab
ZLAB
$2.28B
| $14M | 10.77% |
400,000
| – | – |
|
|
AKRO
4
DELISTED
Akero Therapeutics
AKRO
| $12.4M | 9.55% |
232,446
-10,054
| -4% | -$457K |
|
5
PUT
Eli Lilly
LLY
$1.05T
| $11.7M | 9% |
+15,000
| New | +$11.7M |
|
|
CLLS
6
Cellectis
CLLS
$265M
| $4.97M | 3.82% |
3,256,501
| – | – |
|
|
7
Taysha Gene Therapies
TSHA
$1.71B
| $4.16M | 3.2% |
1,800,556
+545,000
| +43% | +$1.18M |
|
|
8
Ultragenyx Pharmaceutical
RARE
$2.88B
| $4M | 3.08% |
110,000
+62,500
| +132% | +$2.25M |
|
|
9
Sight Sciences
SGHT
$274M
| $3.84M | 2.96% |
930,000
+96,400
| +12% | +$322K |
|
|
10
Aura Biosciences
AURA
$723M
| $3.58M | 2.76% |
572,576
+100,000
| +21% | +$585K |
|
|
11
Assembly Biosciences
ASMB
$531M
| $3.43M | 2.64% |
189,350
-10,650
| -5% | -$140K |
|
12
Iovance Biotherapeutics
IOVA
$2.23B
| $2.58M | 1.99% |
1,500,000
| – | – |
|
|
13
CALL
Ultragenyx Pharmaceutical
RARE
$2.88B
| $2.46M | 1.89% |
67,600
+30,000
| +80% | +$1.08M |
|
14
Apogee Therapeutics
APGE
$10.1B
| $1.52M | 1.17% |
35,000
+5,000
| +17% | +$190K |
|
|
15
Praxis Precision Medicines
PRAX
$8.77B
| $1.47M | 1.13% |
35,000
+16,000
| +84% | +$609K |
|
16
Spyre Therapeutics
SYRE
$8.7B
| $1.2M | 0.92% |
80,000
+10,000
| +14% | +$148K |
|
|
ORKA
17
Oruka Therapeutics
ORKA
$5.59B
| $841K | 0.65% |
75,000
+16,785
| +29% | +$175K |
|
|
18
BioNTech
BNTX
$23.1B
| – | – |
-15,000
| Closed | -$1.37M |
|
19
PUT
Corvus Pharmaceuticals
CRVS
$1.25B
| – | – |
-90,000
| Closed | -$286K |
|
|
ETNB
20
DELISTED
89bio
ETNB
| – | – |
-95,623
| Closed | -$695K |
|
Similar funds
UOP
ICM
EC
AV
FA
GEH
SA
SCM
B Group Inc's Q2 2025 Portfolio in Review
As of Q2 2025, B Group Inc held 20 positions worth $130M, up 11% from $117M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
B Group Inc deployed $7.04M of net new capital in Q2 2025, opening 1 new position and adding to 9 existing holdings.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 99% a quarter earlier.
On the sell side, the largest reduction was Insmed, an estimated $8.22M trimmed.
- B Group Inc added most to Ultragenyx Pharmaceutical in Q2 2025, an estimated $2.25M increase.
- B Group Inc's biggest Q2 2025 reduction was Insmed, cutting an estimated $8.22M.
- B Group Inc fully exited BioNTech in Q2 2025, selling an estimated $1.37M.
- B Group Inc's ten largest holdings make up 90% of its $130M portfolio in Q2 2025.
- B Group Inc opened 1 new position and closed 3 in Q2 2025.
- B Group Inc's portfolio value rose 11% quarter-over-quarter to $130M.
Based on B Group Inc's 13F filing for Q2 2025, filed 14 Aug 2025.